Detalhe da pesquisa
1.
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.
Biol Blood Marrow Transplant
; 25(6): 1128-1135, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30599208
2.
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
Blood
; 129(10): 1389-1393, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049637
3.
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
Biol Blood Marrow Transplant
; 24(2): 343-352, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055682
4.
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.
Biol Blood Marrow Transplant
; 24(10): 2056-2064, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909152
5.
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
Biol Blood Marrow Transplant
; 24(5): 1022-1028, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29353109
6.
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
Biol Blood Marrow Transplant
; 24(5): 1099-1102, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29452245
7.
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.
Biol Blood Marrow Transplant
; 23(11): 1887-1894, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28754545
8.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Blood
; 125(19): 3024-31, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814532
9.
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Haematologica
; 102(2): 391-400, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846611
10.
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
Biol Blood Marrow Transplant
; 21(12): 2115-2122, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26183076
11.
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.
Blood
; 119(18): 4129-32, 2012 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343727
12.
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.
Blood
; 115(11): 2136-41, 2010 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-20018919
13.
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
Biol Blood Marrow Transplant
; 16(4): 482-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19925877
14.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
JCI Insight
; 3(8)2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669947
15.
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.
Blood Adv
; 1(4): 288-292, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242852
16.
Strategies to eliminate cancer stem cells: clinical implications.
Eur J Cancer
; 42(9): 1293-7, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16644203
17.
Cancer stem cell signaling pathways.
Medicine (Baltimore)
; 95(1 Suppl 1): S8-S19, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27611937
18.
Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
J Clin Invest
; 126(12): 4460-4468, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27775549
19.
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.
Leuk Res
; 49: 90-7, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27619199
20.
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
J Clin Oncol
; 33(28): 3152-61, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26261255